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Mansour Esmailidehajd, Mohammad Reza Bigdelie and Ali KhoshbatenfBackgroundHyperoxic preconditioning is known to protect
the heart against necrosis and contractile dysfunction, but
protection against arrhythmias has not been well
characterized.
Objective The authors hypothesized that pre-exposure to
normobaric hyperoxia (H) reduces ischemia and
reperfusion-induced arrhythmias in isolated rat hearts.
Methods Following 60 and 180min of hyperoxia treatment,
rat hearts were isolated immediately (H60 andH180) or 24h
afterward (H60/24 and H180/24), and subjected to 30min
of regional ischemia followed by 120min of reperfusion.
Occurrence, number, and duration of arrhythmias were
analyzed during ischemia and reperfusion. In addition,
cardiac infarct size was also assessed.
Results Sixty and 180min of breathing hyperoxic gas
induced significant protection against severe ischemia and
reperfusion-induced arrhythmias. Total number of
premature ventricular beats was markedly attenuated by
hyperoxia pre-exposure, especially in H60 and H180
groups. Duration of ventricular tachycardia and ventricular
fibrillation was also affected by hyperoxia. Hyperoxia
reduced the number of ventricular tachycardia episodes in
ischemia and reperfusion phase. Accordingly, severity of
arrhythmias (arrhythmia score) and infarct size were loweropyright © Italian Federation of Cardiology. Unau
1558-2027  2009 Italian Federation of Cardiologyin hyperoxia-treated groups. The effects were more
pronounced using hyperoxia immediately before harvesting
the heart.
Conclusion These results indicate that hyperoxic
preconditioning attenuates ventricular ischemia and
reperfusion-induced arrhythmias in isolated rat hearts,
decreases cardiac infarct size, and improves postischemic
heart function. The effects seem to depend on the time
course after hyperoxia treatment. J Cardiovasc Med
10:635–642 Q 2009 Italian Federation of Cardiology.
Journal of Cardiovascular Medicine 2009, 10:635–642
Keywords: hyperoxia, infarct size, ischemia and reperfusion arrhythmias,
isolated rat heart
aDepartment of Physiology, School of Medical Sciences, Tarbiat Modares
University, Tehran, bDepartment of Physiology, Bushehr University of Medical
Sciences, Bushehr, cDepartment of Anatomy, School of Medical Sciences,
Tarbiat Modares University, Tehran, dDepartment of Physiology, Shahid Sadoughi
University of Medical Sciences, Yazd, eDepartment of Biology, Shaheed Beheshti
University, Tehran and fChemical Injuries Research Center, Baqiyatallah
University of Medical Sciences, Tehran, Iran
Corresondence to Professor Sohrab Hajizadeh, PhD, Tarbiat Modares University,
P.O. Box 14115-111, Tehran, Iran
Tel: +98 21 82884521; fax: +98 21 88006544; e-mail: hajizads@modares.ac.ir
Received 10 June 2008 Revised 30 December 2008
Accepted 23 January 2009Introduction
Arrhythmias are one of the important problems in cor-
onary ischemia/reperfusion therapy [1] and constitute a
major risk for sudden cardiac death after coronary artery
occlusion [2]. Therapeutic strategies currently used for
primary prevention of ventricular fibrillation, ventricular
tachycardia, or cardiac arrest remain controversial as few
trials have shown a survival benefit [3]. Recent thera-
peutic methods, such as thrombolysis, coronary bypass
graft surgery, and angioplasty have reduced mortality of
ischemic heart diseases (IHDs), but many patients may
not be suitable candidates for these methods [4]. In
addition, sudden cardiac death caused by ischemia or
reperfusion-induced arrhythmias is a warning to the
development of new antiarrhythmic agents [3]. Finding
new strategies for reducing the degree of primary injury
and/or the rate of dysrhythmias resulting from an
ischemic heart insult could have important clinical con-sequences and could reduce the overall mortality and
morbidity of IHDs.
Brief periods of ischemia and reperfusion before a lethal
ischemic insult, known as ischemic preconditioning
(IPC), have been shown to protect the heart against
ischemia/reperfusion (I/R) injury [5]. However, the appli-
cation of IPC requires a physical cut of the blood supply
which can be difficult or impractical in many clinical
situations. To circumvent these potential problems,
investigations have been directed at finding new thera-
peutic approaches that mimic intracellular signaling of
IPC and induce heart protection.
Hyperoxia is one of the new practical methods for induc-
tion of ischemic tolerance in tissues. In-vivo pre-exposure
to hyperoxia protects the heart against subsequent I/R
injury, as evidenced by attenuated contractile dysfunctionthorized reproduction of this article is prohibited.
DOI:10.2459/JCM.0b013e32832997f3
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induced preconditioning have been confirmed by recent
studies [6,7]. The mechanism of cardioprotection by
hyperoxia seems to be related to the induction of a low-
graded systemic oxidative stress by generation of reactive
oxygen species [7,8]. Protection against arrhythmias has
been proposed as an additional protective aspect of hyper-
oxia. Nevertheless, the role of hyperoxia in protection
against ischemia and/or reperfusion-induced arrhythmias
has not been very well clarified yet. Tahepold et al. [9]
reported that pretreatment with hyperoxia reduces irre-
versible reperfusion arrhythmias in a global model of
ischemia in rat hearts. In another study, combined pre-
treatment of hyperoxia and dexamethasone and hyperoxia
alone decreased the incidence of reperfusion arrhythmias
[10]. In both studies the beneficial effects of hyperoxia
have been examined in the reperfusion; however, neither
of them assessed the effect of hyperoxia during the
ischemic period. By using an isolated rat heart model,
we examined the incidence and severity of ventricular
arrhythmias during ischemia and reperfusion.
Therefore, the aim of the present study was to test the
hypothesis that pre-exposure to normobaric hyperoxia
attenuates ischemia and/or reperfusion-induced arrhyth-
mias in a regional model of heart ischemia both in the first
and second window of protection. We assessed the inci-
dence and severity of ventricular arrhythmias, including
total premature ventricular beats (PVBs), number of
ventricular tachycardia and ventricular fibrillation epi-
sodes, as well as their duration during ischemia and
reperfusion.
Methods
Animals
Male Wistar rats fed a standard diet and tap water ad
libitum and housed at 12 : 12-h light–dark cycle in a stress-
free environment. The experimental protocol used in this
study was approved by the Tarbiat Modares University
Ethics Committee for Animal Research.
Surgical procedure of ischemia/reperfusion injury
Rats were anesthetized with pentobarbital sodium
(60mg/kg, i.p.) and heparinized (300–400 IU, i.p.). After
a bilateral thoracotomy, the heart was dissected from
surrounding structures and placed in ice-cold Krebs–
Henseleit buffer. Then, hearts were immediately cannu-
lated via the aorta and mounted in a Langendorff per-
fusion system and perfused retrogradely with gassed (5%
CO2, 95% O2) Krebs–Henseleit solution [11] (NaCl
118.5mmol/l, NaHCO3 25.0mmol/l, KCl 4.7mmol/l,
KH2PO4 1.2mmol/l, MgSO47H2O 1.2mmol/l, gluco-
seH2O 11.1mmol/l, CaCl22H2O 1.8mmol/l) at 378C
and a constant pressure of 80 cmH2O. A 5-0 silk suture
was loosely placed under the left anterior descending
coronary artery (LAD) 2–3mm from its origin by insert-
ing the needle into the left ventricular wall. The two endsyright © Italian Federation of Cardiology. Unauthof the suture were threaded through a 10mm segment
of tubing, forming a snare. Tightening and loosening
this snare allowed coronary occlusion and reperfusion,
respectively.
An electrocardiogram (ECG) was continuously registered
by means of two stainless-steel electrodes – one attached
to the apex of the heart and the other placed on the right
atrium – and a metal clip was attached to the aortic
cannula as the reference electrode. Heart rate was calcu-
lated from the ECG. ECG and ventricular pressure were
recorded continuously with a computer using a PowerLab
analog to digital converter (AD Instruments, Australia).
Left ventricular systolic (LVSP) and end-diastolic
(LVEDP) pressures were obtained by a latex water-filled
balloon inserted into the left ventricle via the left atrium
and connected to a pressure transducer (MLT 844).
The volume of the balloon was adjusted to obtain end-
diastolic pressure of 5–7mmHg and was unchanged
for the remainder of the experiment. Left ventricular
developed pressure (LVDP) was calculated as ‘LVSP–
LVEDP’. Rate pressure product (RPP) as an index of
cardiac function was calculated by multiplying LVDP by
heart rate (HR). Coronary flow was measured by timed
collections of the coronary effluent.
Experimental protocol
Animals in hyperoxia groups were kept in a hyperoxic
chamber (with oxygen content of95%) for 60 or 180min
(hyperoxia groups), whereas control animals were kept
in the same chamber breathing normal atmospheric air
(normoxic control group). Percentage of oxygen in
inspired air was continuously monitored with an Oxygen
meter (Lutron–DO 5510, Taiwan). Oxygen was continu-
ously delivered into the chamber through a tube. For
assessment of the first window of protection, the hearts
were excised immediately after hyperoxia, and for evalu-
ation of the second window of protection the hearts were
isolated 24 h later for Langendorff perfusion. After a
stabilization time of 20min, the hearts were exposed
to 30min of regional ischemia, followed by 120min of
reperfusion in all experiments. Respective to the treat-
ment prior to heart isolation, the following groups were
investigated: I, normoxic control, breathing normal air
(NC); II, 60min hyperoxia immediately before heart
isolation (H60); III, 180min hyperoxia immediately
before heart isolation (H180); IV, 60min hyperoxia
24 h before heart isolation (H60/24); V, 180min hyperoxia
24 h before heart isolation (H180/24).
Determination of infarct size
At the end of 120min reperfusion, the coronary artery was
re-occluded, and the risk zone was delineated by perfus-
ing 1ml of 2%Evans blue solution into the aortic cannula.
After freezing at 208C, hearts were cut into five or six
transverse slices of 2mm thickness from apex to the base
and the slices were incubated in 1% triphenyl tetrazoliumorized reproduction of this article is prohibited.
CIschemia/reperfusion arrhythmias and hyperoxia Pourkhalili et al. 637chloride (TTC, Sigma) at 378C for 20min. Viable myo-
cardium is stained in red by TTC, whereas infarcted
tissue remains unstained. The slices were then photo-
graphed by a digital camera (Olympus, FE–160). Area at
risk (AAR) and infarct size were determined by compu-
terized planimetry using an image analysis software
(Image Tool; available at http://ddsdx.uthscsa.edu/dig/
itdesc.htm/). The infarcted area was calculated as per-
centage of AAR.
Quantification of arrhythmias
Arrhythmias were defined according to the Lambeth
Conventions [12]. Accordingly, arrhythmias were cate-
gorized as PVBs (defined as discrete premature ventri-
cular depolarization), ventricular tachycardia (a run of
four or more consecutive ventricular premature beats),
and ventricular fibrillation (a signal in which individual
QRS wave deflections could not easily be distinguished
from each other). More complex forms (e.g. bigeminy and
salvos) were included in the count of ventricular prema-
ture beats and were not analyzed separately.
Electrocardiograms were analyzed for the total number of
PVBs and the incidence and duration of ventricular
tachycardia and ventricular fibrillation during 30min of
ischemia and 120min of reperfusion. In addition, severity
of arrhythmias was quantified by a scoring system. Each
individual heart was evaluated by means of a five-point
arrhythmia score, in which single PVBs were given a scoreopyright © Italian Federation of Cardiology. Unau
Table 1 Cardiac function data in isolated rat hearts subjected to 30m
Parameters/groups Stabilization (20 min) Ischemia (30 min) 3
HR (beats/min)
NC 3018 26110 26
H60 29911 27920 32
H180 33318 30223 29
H60/24 3309.0 32718 30
H180/24 32222 28819 31
LVDP (mmHg)
NC 76.93.3 58.53.0 74
H60 80.73.9 60.22.0 72
H180 75.83.4 58.60.9 77
H60/24 72.31.8 56.61.9 73
H180/24 77.33.7 59.22.3 73
RPP (mmHg beats/min)
NC 23126988 14409713 1914
H60 240321259 166851122 2338
H180 251011422 177641486 2326
H60/24 23245979 185461244 2269
H180/24 248621954 16909948 2267
Coronary flow (ml/min)
NC 10.40.9 4.70.7 7
H60 10.10.5 5.50.9 9
H180 10.31.1 5.01.0 10
H60/24 10.90.5 4.50.8 9
H180/24 9.80.8 4.60.4 8
Functional heart parameter recovery was analyzed during reperfusion. Data presented a
before heart isolation; H180, 180 min hyperoxia immediately before heart isolation; H60
before heart isolation. HR, heart rate; LVDP, left ventricular developed pressure; RPP, ra
point.of 1, bigeminy/salvos a score of 2, ventricular tachycardia
a score of 3, ventricular fibrillation a score of 4, sVF
(ventricular fibrillation lasting more than 2min) a score
of 5, and an assigned number corresponded to the most
severe type of arrhythmia observed in that heart. Scores
were used for group analysis of severity of arrhythmias.
Statistics
Data were expressed as meansSEM. The incidence of
arrhythmias was presented as percentage of occurrence.
Comparison of differences in the recovery of post-
ischemic functional parameters, infarct size, and number
of arrhythmias were tested by one-way ANOVA with
Duncan’s post-hoc analysis. Fisher’s Exact test was used
for comparison of the incidences of ventricular tachycar-
dia and ventricular fibrillation. Differences in the arrhyth-
mias score, ventricular tachycardia and ventricular fibril-
lation duration between the groups were compared by the
Mann–Whitney U-test. P-value of less than 0.05 was
considered statistically significant.
Results
Cardiac function parameters
Table 1 summarizes HR, LVDP, RPP, and coronary flow
in all groups determined at 20min of stabilization period;
at 30min after coronary artery occlusion; and at 30, 60, 90,
and 120min of reperfusion. As shown, the baseline
functional parameters were not significantly different
between the normoxic control and hyperoxia groups.thorized reproduction of this article is prohibited.
in of ischemia and 120min reperfusion
Reperfusion
0 min 60 min 90 min 120 min
315 26217 26322 24119
215 31015 28814 27414
916 30016 28817 27818
74.0 3006.0 2915.0 28614
428 28024 25629 25028
.02.8 70.42.0 65.91.8 61.41.4
.71.0 69.51.2 67.11.3 66.60.8
.81.2 72.51.7 71.01.7 68.11.0
.81.9 70.62.2 67.52.8 66.93.4
.32.7 71.83.3 69.43.4 65.42.8
91283 183831527 171321289 147521134
21051 21518979 19350962 18270918
71470 218641463 20653619 190001314
1568 21216338 19621833 18988689
81351 198921266 174981505 161301447
.81.2 6.60.8 5.10.5 4.60.5
.40.9 7.60.4 6.30.8 5.50.8
.90.6 8.90.5 7.70.4 6.60.7
.10.7 7.50.4 6.21.0 5.20.7
.70.5 7.60.7 6.40.7 5.60.6
s mean SEM. Groups: NC, normoxic control; H60, 60 min hyperoxia immediately
/24, 60 min hyperoxia 24 h before heart isolation; H180/24, 180 min hyperoxia 24 h
te pressure product.

P<0.05 compared to normoxic control group at each time
Cop
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Fig. 1
Graphs represent percentages of area at risk by the total heart area (a),
and percentages of infarct size (IF) by the area at risk (b). Area at risk
(AAR) in all groups is identical. NC: normoxic control group (n¼10);
H60: 60 min hyperoxia (>95% O2) pretreatment immediately before
heart isolation (n¼7); H180: 180 min hyperoxia pretreatment
immediately before heart isolation (n¼8); H60/24: 60 min hyperoxia
pretreatment 24 h before heart isolation (n¼6); H180/24: 180 min
hyperoxia pretreatment 24 h before heart isolation (n¼6). Data are
presented as meanSEM. () P<0.01 compared to normoxic
control and () P<0.05 compared to NC.RPP as an index of cardiac function was increased in H60
and H180 groups compared to normoxic control group
at different time points during reperfusion (P< 0.05).
Coronary flow rate was also significantly greater in H60
and H180 groups vs. normoxic control group (P< 0.05).
Normalizing the data as mean percentage of decrease in
cardiac function parameters during reperfusion in com-
parison to baseline shows that coronary flow was reduced
36% in the normoxic control group with respect to its
baseline, which was significantly different from H60
(19%, P< 0.05) and H180 (9%, P< 0.001) groups. There
was also a significant difference between the H180 group
and other hyperoxia-treated groups (P< 0.05). This
change for LVDP and RPP in reperfusion compared to
baseline was not significant.
Area at risk and infarct size
Area at risk did not differ significantly among the groups
(Fig. 1a). In the normoxic control group 39.5 3.6% of
AAR was necrotic at the end of 2 h reperfusion. Pretreat-
ment with hyperoxia for 60 (H60) and 180 (H180) minutes
immediately before heart isolation reduced infarct size to
26.3 2.3 (P< 0.05) and 20.4 2.6% (P< 0.01), respec-
tively. Hyperoxia for 60 (H60/24) and 180 (H180/24)
minutes, 24h before heart isolation also significantly
reduced infarct size to 25.8 3.8 and 24.3 3.9%, respec-
tively (P< 0.05) (Fig. 1b).
Arrhythmia studies during ischemia
Table 2 summarizes the effects of hyperoxic precondi-
tioning on the severity of arrhythmias during 30min of
ischemia. Episodes of PVBs occurred in all groups. The
total number of PVBs in the normoxic control group was
344 54. Hyperoxia reduced the total number of PVBs in
H60 and H180 groups (192 30 and 219 21, respect-
ively, P< 0.05) compared to the normoxic control group.
The reduction was also significant in the H180/24 group
(P< 0.01). Duration of ventricular tachycardia and
ventricular fibrillation was assessed during 30min of
ischemia. The mean duration of ventricular tachycardia
episodes in the normoxic control group was 45.18 7.5 s.
Sixty minutes’ hyperoxia immediately before heart iso-
lation significantly decreased ventricular tachycardia
duration (17.9 4 s, P< 0.05). The reduction of ventri-
cular fibrillation duration by hyperoxia was not statisti-
cally significant during ischemia. In addition, number of
ventricular tachycardia episodes was also affected byyright © Italian Federation of Cardiology. Unauth
Table 2 Effects of hyperoxic preconditioning on the number of prematur
duration, and their episode number during 30min of ischemia
Groups n PVBs Ventricular tachycardia duration (s) Ventricular fibrillatio
NC 11 34454 45.187.5 18.81
H60 10 19230 17.94 4.54
H180 8 21921 23.86.3 0.90
H60/24 7 32928 39.75.7 19.52
H180/24 8 18023 29.47.7 161
PVBs, premature ventricular beats. Data are meanSEM. P<0.05 compared withhyperoxia pretreatment, so that there was a significant
decrease in number of ventricular tachycardia episodes in
H60, H180, and H180/24 groups compared to the nor-
moxic control group. Arrhythmia score was assigned on
the basis of the most severe arrhythmia detected in
each experiment.
Arrhythmia score in the normoxic control group was
3.54 0.2 which was significantly attenuated to 2.9
0.18 by 60 and 2.87 0.22 by 180min of hyperoxiaorized reproduction of this article is prohibited.
e ventricular beats, ventricular tachycardia and ventricular fibrillation
n duration (s) Ventricular tachycardia episodes Ventricular fibrillation episodes
2.5 37.34.7 0.810.32
.5 13.23 0.200.20
.9 205.8 0.120.12
0.2 34.36 0.710.47
6 18.94.5 0.120.12
normoxic control.

P<0.01 compared with normoxic control.
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Fig. 2
Arrhythmias severity evaluated by means of arrhythmia score. (a) arrhythmia score in ischemia. (b) Arrhythmia score in reperfusion. Data are
meanSEM. () P<0.05 compared to normoxic control group (NC).immediately before heart isolation (P< 0.05) (Fig. 2a).
The decrease in ventricular tachycardia and ventricular
fibrillation incidence was not significant during ischemia
(see Table 4).
Arrhythmia studies during reperfusion
Incidence and severity of arrhythmias were also analyzed
during 120min of reperfusion. The total number of PVBs
in normoxic control groupwas 701 82. Pretreatmentwith
hyperoxia reduced the total number of PVBs in H60 and
H180 groups to 266 60 and 225 36, respectively. The
ventricular tachycardia duration for normoxic control
group was 17.7 3.3 s. This time markedly decreased in
H60 andH180 groups: 1.5 0.7 s (P< 0.01) and 7.5 2.5 s
(P< 0.05), respectively.Duration of ventricular fibrillation
was also decreased in the H180 group compared to nor-
moxic control (0 vs. 50 31 s, P< 0.05). Duration of ven-
tricular tachycardia and ventricular fibrillation was not
significantly reduced by hyperoxia 24h before heart iso-
lation (Table 3).opyright © Italian Federation of Cardiology. UnauThe incidence of ventricular tachycardia did not differ
significantly among the normoxic control and the hyper-
oxia pretreatment groups. There were no significant
differences in the incidence of ventricular fibrillation
between H60, H60/24, and H180/24 with normoxic con-
trol group. On the contrary, pretreatment with 180min of
hyperoxia immediately before heart isolation (H180)
completely abolished the incidence of ventricular fibril-
lation (0 vs. 50% of normoxic control, P< 0.05) (Table 4).
Severity of arrhythmias that was evaluated by means of
arrhythmia score was also affected by hyperoxia. Arrhyth-
mia score in the normoxic control group was 3.7 0.26,
which was significantly attenuated to 2.6 0.18 by
180min hyperoxia immediately before heart isolation
(P< 0.05) (Fig. 2b).
Discussion
The main findings of the present study show that pre-
exposure to normobaric hyperoxia (95% O2) has an
antiarrhythmic effect against ischemia and reperfusion-thorized reproduction of this article is prohibited.
Cop
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Table 3 Effects of hyperoxic preconditioning on the number of PVBs, ventricular tachycardia and ventricular fibrillation duration, and their
episode number during 120min of reperfusion
Groups n PVBs
Ventricular tachycardia
duration (s)
Ventricular fibrillation
duration (s)
Ventricular tachycardia
episodes
Ventricular fibrillation
episodes
NC 10 70182 17.73.3 5030.6 8.91.9 0.90.4
H60 7 26660 1.50.7 26.526.5 2.31 0.140.14
H180 8 22536 7.52.5 0 5.11.9 0
H60/24 6 49097 9.92.5 58.435.3 51.1 10.51
H180/24 6 36594 15.23.6 2.82.8 5.81.7 11
PVBs, premature ventricular beats. Data are meanSEM. P<0.05 compared with normoxic control. P<0.01 compared with normoxic control. P<0.001
compared with normoxic control.induced arrhythmias and protects hearts from I/R injury.
The effects were more obvious for hyperoxia exposure
immediately before heart isolation. Our work may have
clinical relevance because 50%of sudden death in humans
is due to ventricular tachycardia or ventricular fibrillation
and the remainder to bradyarrhythmias or electromecha-
nical dissociation [13].
There are only limited numbers of studies showing
antiarrhythmia effect of hyperoxia [9,10]. In these studies
the beneficial effects of hyperoxia were reported in the
reperfusion period; however, none of them reported the
effect of hyperoxia during the ischemic period. In our
previous study we showed that pre-exposure to 60, 120,
and 180min of normobaric hyperoxia (>95%) 24 h before
ischemia significantly decreases incidence and severity of
ischemic arrhythmias in anesthetized rat hearts [14].
Here we observed that hyperoxia lowered ventricular
fibrillation incidence during the reperfusion phase in a
regional model of rat heart ischemia. This result is in line
with the results presented by Tahepold et al. [9]. More-
over our results show that hyperoxia dramatically lowered
the number of PVBs, ventricular tachycardia and ventri-
cular fibrillation duration, and the number of ventricular
tachycardia and ventricular fibrillation episodes during
reperfusion. We also provided the first evidence that, in
addition to reducing the incidence of reperfusion arrhyth-
mias, hyperoxia also decreases the severity of arrhythmias
during ischemia. To our knowledge, this is the first
experimental evidence showing that hyperoxia reduces
the severity of arrhythmias during the ischemic phase.
Hyperoxia for 60 and 180min immediately before heart
isolation decreased infarct size, improved coronary flow,
and increased recovery of heart function. In addition,yright © Italian Federation of Cardiology. Unauth
Table 4 Incidence of ventricular tachycardia and ventricular fibrillation
Ischemia
Groups Ventricular tachycardia (%) Ventricular fibrillation (%
NC 100 45.4
H60 80 10
H180 75 12.5
H60/24 100 28.5
H180/24 87.5 12.5

P<0.05 compared with normoxic control.some of the protective effects of hyperoxia persisted 24 h
after treatment, showing a second window of protection.
The reduction of infarct size in our study was in con-
cordance with the reduction of LDH and creatine kinase
release into the coronary effluent (data are not shown).
The most powerful cardioprotective effects of hyperoxia
were seen in 180min pretreatment with hyperoxia
immediately before heart isolation.
One of themajor determinants of arrhythmogenesis is the
size of ischemic zone [15]; however, this factor was
disregarded since there were no differences in the size
of AAR between the groups. On the contrary, changes in
infarct size correlate well with antiarrhythmic effects of
hyperoxia. Therefore, it appears that the extent of myo-
cardial infarct size may directly affect arrhythmogenesis.
Despite its cardioprotective properties, the actual mech-
anisms of hyperoxia antiarrhythmia effects have not been
elucidated. Several studies indicate that reactive oxygen
species (ROS) participate in the signaling pathway
involved in preconditioning triggering [16–18]. On the
contrary, antioxidant administration abolished the cardio-
protective effects of IPC [19]. The mechanisms by
which ROS are responsible for this cardioprotective
effect are not well recognized; however, it seems that
ROS both indirectly, through the activation of protein
kinases, and directly lead to the activation of some
transcription factors such as nuclear factor kappa B
(NF-kB), which in turn trigger genes related to tissue
protection, including Bcl-2 [7,20]. ROS also could acti-
vate protein kinase C (PKC) which in turn prevents the
opening of mitochondrial permeability transition pores
(MPTP). Breathing a hyperoxic gas mixture leads to an
elevated level of ROS generation due to higher O2orized reproduction of this article is prohibited.
Reperfusion
) Ventricular tachycardia (%) Ventricular fibrillation (%)
100 50
71.4 14.28
62.5 0

83.3 50
83.3 16.7
CIschemia/reperfusion arrhythmias and hyperoxia Pourkhalili et al. 641tension in inspired air than normal values in the body
[21,22]. Therefore, observed cardioprotective effects of
hyperoxia may be mediated via ROS generation.
In addition to ROS, hyperoxia also induces its cardiopro-
tective effects through the generation of nitric oxide. In a
study of the response to hyperoxia, 1 h of exposure to
hyperbaric hyperoxia (2 atm, 100%) increased nitric oxide
synthase 3 (NOS3) expression that resulted in elevated
nitric oxide levels in the rat heart [23]. Valen et al. [24]
found that mice deficient for the inducible nitric oxide
synthase gene could not be protected by classic ischemic
or hyperoxic preconditioning. In another study Nv-nitro-
1-arginine methyl ester (L-NAME) administration prior
to hyperoxia pretreatment blocked the cardioprotective
effects of hyperoxia [25]. Taken together, these results
suggest that nitric oxide is an important mediator of
hyperoxic preconditioning. Moreover, studies show that
nitric oxide itself is responsible for induction of both the
first and second window of protection by IPC [26]. Thus
it could be speculated that observed immediate and 24 h
later cardioprotective effects of hyperoxia are mediated
by nitric oxide.
One of the proposed mechanisms of nitric oxide action is
through a nitric oxide–cGMP–protein kinase G (PKG)
signaling pathway, and mitochondrial Kþ-ATP channels
and PKC as the downstream targets [27,28]. The acti-
vation of these channels may improve the recovery of
regional contractility of myocardium by shortening the
duration of action potentials and by attenuating mem-
brane depolarization, both of which would decrease myo-
cardial contractility and reduce energy expenditure
during ischemia [26]. Also, opening of mitochondrial
Kþ-ATP channels may lead to ROS generation, which
in turn would be responsible for the activation of PKC
[29]. The role of mitochondrial Kþ-ATP channels as one
the end effectors of hyperoxic preconditioning has been
also established [22]. Thus according to these results, and
evidence for the proved antiarrhythmic role of mitochon-
drial Kþ-ATP channels in IPC [30], it can be suggested
that the antiarrhythmia effect of hyperoxia mediates
through the pathway of nitric oxide–cGMP–PKG–mito-
chondrial Kþ-ATP channels.
Another possible mechanism of nitric oxide action is
through the combination of nitric oxide with superoxide
to from peroxynitrite which is responsible for the induc-
tion of the second window of protection by up-regulation
of PKC, which in turn up-regulates inducible nitric oxide
synthase (iNOS) by activation of the transcription factor
NF-kB. Experimental results also support a cardiopro-
tective and antiarrhythmic role for peroxynitrite [31].
Peroxynitrite has been shown to contribute to the cardi-
oprotective effects of IPC in rats [31]. Thus it is con-
ceivable that hyperoxia may induce its cardioprotective
effects through release of nitric oxide, with subsequentopyright © Italian Federation of Cardiology. Unauaccumulation of peroxynitrite produced through inter-
action with superoxide. This suggestion is supported by a
recent review in which part of the effects of hyperoxia
were attributed to the formation of peroxynitrite from
nitric oxide and superoxide anion following hyperoxic gas
exposure [32].
Although the results of the present study and others
[9,10,14] clearly show a beneficial effect of hyperoxia
pre-exposure against ischemia and/or reperfusion-
induced arrhythmias in rat hearts, there are also contra-
dictory results, indicating an arrhythmogenic effect of
severe hyperoxia. Wittnich et al. [33] showed that expos-
ing neonatal pig hearts to severe hyperoxia (500mmHg,
5 h) increases the incidence of ventricular fibrillation
during global ischemia. In another study Pifarre et al.
[34] reported a ventricular fibrillation incidence increase
following regional ischemia in dog hearts. At present we
have no explanation for this discrepancy, but it may be
due to a species difference.
Usage of hyperoxia in a clinical human setting would be
very attractive. It has been shown that hyperoxygenation
therapy is well tolerated by humans if administrated
according to the standard protocols. In this regard, admin-
istration of 80% oxygen for less than 24 h is considered
well tolerated [35]. Because in rats the first histological
findings of oxygen toxicity will appear in the lung tissue
only after about 40 h of pure oxygen administration [36],
it seems that there is a wide safety window between
protective effects of oxygen pretreatment and its toxic
effects. However, this is the case in healthy lungs, and in
lungs that are already diseased, or in lungs that are
exposed to multiple risk factors and/or for acute lung
injury (as seen in coronary artery bypass grafting using
extracorporeal circulation); a much shorter exposure to
hyperoxia has the potential to cause lung injury.
The most important advantage of short-term normobaric
hyperoxia pretreatment as a preconditioning model com-
pared to other methods is its simplicity and easy clinical
applicability. In addition, increasing O2 tension in blood
affects other organs in the body and may even induce a
whole-body preconditioning-like effect which could be
very useful in critical surgery. Although perioperative
oxygen administration has known advantages, such as
decreasing wound infection or nausea and vomiting [35],
there may still be a long way to go before approving the
use of oxygen with this new potential indication (PC
induction) before surgery.
On the basis of the results obtained in present study it
could be concluded that pretreatment with normobaric
hyperoxia alleviates ischemia and reperfusion arrhyth-
mias in isolated rat heart and that this protective effect is
more obvious immediately after hyperoxia pretreat-
ment. Additionally hyperoxia improves cardiac functionthorized reproduction of this article is prohibited.
Cop
642 Journal of Cardiovascular Medicine 2009, Vol 10 No 8parameters and reduces infarct size. Irrespective of the
precise mechanisms of these beneficial effects, hyperoxia
could be a potentially useful preconditioning method in
clinical situations.
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